Dilip Shanghvi

The just completed Ranbaxy deal, its biggest to date at USD 3.2 billion, has given India's biggest drugmaker sufficient scale in generics and emerging markets to think about its next step - beefing up expertise in higher margin products and gaining a bigger global presence.

The company was clarifying on speculations that Sanghvi, who holds 9.61 percent stake in Sun Pharma, had bought shares when Daiichi Sankyo exited from the Indian firm.

Shanghvi, who replaced Mukhesh Ambani as India‘s richest man on March 4, said the company's "most important focus" would be to regain the confidence of regulators. The company aims to grow faster than the market in each of its business, he added.

The market remained in a consolidation more on Wednesday ahead of expiry of derivative contracts of March series. The broader markets too were rangebound but lost ground in last hour of trade.

The merger has fortified Sun Pharma's position as the world's fifth largest speciality generic pharmaceutical firm and the top ranking Indian pharma company with significant lead in market share, it added.

The company will look to invest more than USD 300 million in research and development and is not considering any job cuts post the close of the deal, Managing Director Dilip Shanghvi told reporters in Mumbai.

Shares of Sun Pharmaceutical Industries and Ranbaxy Laboratories gained 2.5 percent each intraday on Thursday on news the Sun has formed new leadership team for merged entity.

While the leadership team is comprised mainly from the representatives of Sun Pharma, it also has executives from Ranbaxy, drawing upon expertise, experience and contribution of the chosen leaders from both the organisations.

As per a 'real time' update from business magazine Forbes, known for its annual rich lists, Sun Pharma Group's Shanghvi was ranked richest Indian, followed by Mukesh Ambani and tech czar Azim Premji at second and third positions, respectively, among Indians.

Among the 90 Indians on the Forbes Rich List 2015, published on Monday, Ambani (39th globally) is closely followed by pharmaceuticals business tycoon Dilip Shanghvi (44th rank with networth of USD 20 billion) and Azim Premji (48th with USD 19.1 billion).

Shares of Suzlon Energy today surged over 7 percent amid reports that Sun Pharma's Dilip Shanghvi will provide as much as Rs 3,800 crore of security that will help the wind turbine maker in availing credits.

Ups and downs are part and parcel of wealth creation. This list reflects just that. Here are the biggest gainers and losers over the last year, ranked in terms of percentage change in net worth

The Forbes India rich list shows modest gains for India's richest due to a stumbling economy. Steel magnate Lakshmi Mittal also retains his No.2 position on the rich list with a wealth of USD 16 billion.

With networth of USD 21.5 billion, Mukesh Ambani has retained his title as India's richest person for sixth year in a row, while Mexican business tycoon Carlos Slim has emerged as wealthiest in the world for the fourth consecutive year.

Dilip Shanghvi built Sun Pharma into one of the most profitable generic drugs companies in the world. Now, he's stepped back and brought in Israel Makov to steer Sun into its next growth phase.

Sun Pharmaceutical Industries today said it plans to invest Rs 450 crore for capacity expansion and upgradation of existing plants, including its Taro facilities, in the current fiscal.

Sun Pharmaceutical Industries expects revenue to rise 28-30% in the year ending March 2012, a top company official said on Monday.